Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02740127
Other study ID # 2014-0990
Secondary ID NCI-2016-00860
Status Completed
Phase Phase 3
First received
Last updated
Start date June 2016
Est. completion date May 10, 2020

Study information

Verified date January 2022
Source M.D. Anderson Cancer Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

During penile prosthesis surgery, patients are given general anesthesia in combination with other pain drugs. A caudal nerve block (CNB) is a local anesthetic injected near the tailbone, in addition to general anesthesia, which can lower the need for pain drugs. The goal of this clinical research study is to learn how effective CNBs are in patients who are having penile prosthesis surgery compared to patients who only have general anesthesia by studying how long you stay in the hospital and the level of pain you have after surgery. This is an investigational study. The general anesthesia and CNB used in this study are FDA approved and commercially available. It is considered investigational to compare the effectiveness of CNBs in penile prosthesis surgery to general anesthesia alone. The study doctor can explain how the study drugs are designed to work. Up to 104 participants will be enrolled in this study. All will take part at MD Anderson.


Description:

Study Groups and CNB Administration: If you are found to be eligible to take part in this study, you will be randomly assigned (as in the flip of a coin) to 1 of 2 study groups. You will have an equal chance of being assigned to either group. - If you are assigned to Group 1, you will receive a CNB and general anesthesia during surgery. - If you are assigned to Group 2, you will only receive general anesthesia during surgery. You will not know to which group you have been assigned. The CNB will be given to you while you are under general anesthesia. To receive a CNB, a special needle is inserted at the lower part of the back (near the tailbone). A type of local anesthesia is then injected into the sac surrounding the spinal cord that contains the nerves related to the penis. All participants will also receive general anesthesia as part of their standard care. You will also receive a separate consent form for the surgery that explains the procedure and its risks, including the risks for general anesthesia. After Surgery Data Collection: During the 24 hours after surgery, the study staff will ask you to rate your pain on a scale of 0-10. You will be asked to rate your pain about every 30 minutes while you are in the hospital, but you may be asked to rate your pain more often if needed. It should take less than 5 minutes each time to rate your pain. Depending on how you rate your pain, additional pain drugs may be given to you as part of your standard care. If you are discharged from the hospital on the same day as your surgery or if you are discharged before a member of the staff can ask you to rate your pain, the study staff will call you within 24 hours after you have been discharged from the hospital. This call should last about 5-10 minutes. The amount of pain drugs given to you before, during, and after surgery will also be recorded. About 3 days after your surgery, the study staff will call you to ask about your pain, the amount of pain drugs you have taken, and how satisfied you are with the type of anesthesia and pain control you have received. This call should last about 5-10 minutes. Length of Study: Your participation in this study will be over after the phone call about 3 days after your surgery has been completed.


Recruitment information / eligibility

Status Completed
Enrollment 52
Est. completion date May 10, 2020
Est. primary completion date May 10, 2020
Accepts healthy volunteers No
Gender Male
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Patients that consent to participate. 2. Patients undergoing penile prosthesis surgery. 3. Patients that are male. 4. Patients that are 18 years of age or older. Exclusion Criteria: 1. Patients on chronic pain medications (ie. Chronic = more than once every two days for greater than 2 weeks) excluding Aspirin, Acetaminophen and NSAIDs. 2. Patients with a BMI > 40. 3. Patients with chronic pain syndromes. 4. Patients with hypersensitivity to Ropivacaine/amide-type anesthetics. 5. Prior surgery of the sacrum. 6. Patients taking anti-coagulants or other blood thinning medications prior to surgery during the specified time frames: i) Low molecular weight heparin less than 36 hours prior to surgery. ii) Coumadin less than 5 days prior to surgery. iii) Plavix and NSAIDs less than 7 days prior to surgery. 7. Patients on any anti-seizure medications, such as gabapentin or Lyrica, specifically for chronic pain management less than 24 hours prior to surgery 8. Patients on Celebrex less than 24 hours prior to surgery 9. Patients taking more than 81 mg of Aspirin daily

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Caudal Nerve Block (CNB)
General anesthesia given in the OR using Propofol titrated for induction. CNB given as bolus injection into the caudal canal in the operating room (OR) by attending anesthesiologist using 1% Ropivacaine (max 5mg/kg) + 1:400,000 Epinephrine + Decadron 10 mg + Clonidine 100 mcg.
Drug:
Ropivacaine
Ropivacaine 1 % (max 5mg/kg) by bolus injection given by anesthesiologist in OR.
Epinephrine
Epinephrine 1:400,000 by bolus injection given by anesthesiologist in OR.
Decadron
Decadron 10 mg by bolus injection given by anesthesiologist in OR.
Clonidine
Clonidine 100 mcg by bolus injection given by anesthesiologist in OR.
Propofol
General anesthesia given in the OR using Propofol titrated for induction.
Behavioral:
Phone Call
Study staff calls participant about 3 days after surgery to ask about their pain, amount of pain drugs they have taken, and how satisfied they are with the type of anesthesia and pain control they received. This call should last about 5-10 minutes.

Locations

Country Name City State
United States University of Texas MD Anderson Cancer Center Houston Texas

Sponsors (2)

Lead Sponsor Collaborator
M.D. Anderson Cancer Center Merck Sharp & Dohme Corp.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Post-Operative Pain Medication Usage in Post Anesthesia Care Unit (PACU) Pain evaluated by the amount of intravenous and oral pain medicine administered in the first 24 hours post-operatively. Pain assessed using the numeric rating scale (NRS). The NRS is scored by numeric integers, 0 through 10, where 0 is no pain and 10 is the worst pain. 24 hours
Secondary Post-operative Pain the First 24hrs To determine whether the use of a CNB in patients undergoing penile prosthesis surgery results in decreased immediate postoperative pain in the first 24 hours after surgery compared with patients having only general anesthesia as determined by postop pain score. The mean, median and max pain will be assessed using the numeric rating scale (NRS). The NRS is scored by numeric integers, 0 through 10. The NRS will be used verbally. Numerical Rating Scale (NRS), patients are asked to circle the number between 0 and 10 that fits best to their pain intensity. Zero usually represents 'no pain at all' whereas the upper limit represents 'the worst pain ever possible' 24 hours
Secondary Length of Hospital Stay To determine whether the use of a CNB in patients undergoing penile prosthesis surgery results in a decreased length of hospital stay compared with patients having only general anesthesia. 32 Hours
See also
  Status Clinical Trial Phase
Withdrawn NCT02812056 - Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associated Malignancies Phase 1
Completed NCT03210376 - Neuromuscular Blockade on Shoulder Pain of Elderly Phase 4
Withdrawn NCT03035357 - Neoadjuvant Listeria or Daratumumab in Prostate Cancer Phase 2
Active, not recruiting NCT03435952 - Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT Phase 1
Withdrawn NCT02915172 - Lenvatinib and Capecitabine in Patients With Advanced Malignancies Phase 1
Active, not recruiting NCT03162627 - Selumetinib and Olaparib in Solid Tumors Phase 1